Tags & Categorías

As Adalimumab Biosimilar Competition Heats Up, AbbVie Sues Sandoz

This month, AbbVie filed suit against biosimilar developer Sandoz over its proposed adalimumab (Humira) biosimilar. The suit was filed in the District...

Review Documents 15 Years of Experience With Adalimumab in Psoriasis

This Psoriasis Awareness Month, a new review of real-world experience with adalimumab (Humira) in patients with psoriasis finds that adalimumab is sli...

Patients Treated With Tocilizumab May Be Able to Discontinue Methotrexate

Combination treatment is typically more effective than treatment with methotrexate alone, but some patients may experience adverse events with methotr...

Celltrion's Korean Plant Receives Another Form 483

Celltrion’s Korean plant has received its second Form 483 from the FDA in less than a year, only months after having received a warning letter for ...

La CIPM aprueba tres biosimilares de enoxaparina y un trastuzumab

La Comisión Interministerial de Precios de los Medicamentos (CIPM) del pasado 25 de mayo aprobó para su comercialización en España los tres primer...

CHMP approves pegfilgrastim biosimilar, Pelgraz

Pelgraz – a pegylated G-CSF biosimilar, is latest addition to Accord Healthcare’s established portfolio of over 30 oncology treatments across Euro...

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and de...

Once nuevos biosimilares llegarán a corto plazo, seis para la farmacia

Entre los próximos lanzamientos hay dos adalimumab y un trastuzumab que aspiran a competir frente a ‘Humira’ y ‘Herceptin’. También se sumar...

Congressman Sarbanes Introduces Biosimilars Competition Act of 2018

Yesterday, Congressman John Sarbanes, D-Maryland, introduced the Biosimilars Competition Act of 2018 in the United States House of Representatives. ...